Latest Daiichi Sankyo News & Updates

See the latest news and media coverage for Daiichi Sankyo. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Daiichi Sankyo

Global pharmaceutical research and development company

daiichisankyo.com
Headquarters
Chuo-ku, Japan
Company type
Public company
Number of employees
10,000+
Industry
Pharmaceuticals

Last updated

Latest news about Daiichi Sankyo

In short: Daiichi Sankyo secured key drug approvals for Enhertu and Datroway in the EU and Japan and won a major 203 billion yen legal battle.

Company announcements

Daiichi Sankyo

Daiichi Sankyo starts phase 3 trial for urothelial cancer

The trial evaluates a DXd antibody-drug conjugate in combination therapy for adjuvant treatment of patients with high-risk muscle invasive disease.

Unlock all announcements with a

Media coverage

Nikkei

Daiichi Sankyo's "Enhertu" and "Trodelvy" approved for metastatic breast cancer ...

Daiichi Sankyo announced that it has obtained additional approvals for the anticancer drugs "Enhertu" and "Trodelvy" as first-line treatments for patients with metastatic breast cancer. Enhertu is indicated in combination with pertuzumab for "HER2-positive unresectable or recurrent breast cancer," and Trodelvy is indicated for "hormone receptor-negative and HER2-negative unresectable or...

Reuters

Daiichi Sankyo Co Ltd

AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been approved...

Unlock all articles with a

Never miss news about Daiichi Sankyo

Track Daiichi Sankyo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Daiichi Sankyo competitors & trending companies

Browse news for competitors to Daiichi Sankyo and other trending companies.